Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Warning Letter
  6. /
  7. K. Boeun Pharmaceutical Co., Ltd.
WARNING LETTER
•K. Boeun Pharmaceutical Co., Ltd.•August 11, 2023

K. Boeun Pharmaceutical Co., Ltd. – FDA Warning Letter, Aug 11, 2023

Record Details

The FDA issued a Warning Letter to K. Boeun Pharmaceutical Co., Ltd. (FEI 3016756938) on August 14, 2023, following a review of records submitted per a March 3, 2023, request under section 704(a)(4) of the FD&C Act. The facility, an OTC drug product manufacturer, was found to have significant Current Good Manufacturing Practice (CGMP) violations, rendering its drug products adulterated under 21 U.S.C. 351(a)(2)(B).

Key violations include: 1. **Failure to conduct identity testing for drug components (21 CFR 211.84(d)(1)):** The firm did not adequately test each shipment of high-risk components like glycerin and sorbitol solution for diethylene glycol (DEG) or ethylene glycol (EG) contamination using USP identification tests. This poses a significant safety risk. 2. **Inadequate Quality Control Unit (QCU) (21 CFR 211.22(a)):** The QCU failed to effectively oversee drug manufacturing operations, specifically in approving or rejecting components in the Materials System. Concerns were raised about potential lack of oversight in other CGMP areas like Production, Facilities & Equipment, Laboratory Controls, and Packaging & Labeling.

The FDA recommends engaging a qualified CG

Company
K. Boeun Pharmaceutical Co., Ltd.
Inspection date
August 11, 2023
Product type
Drugs
Office
Center for Drug Evaluation and Research
People
  • Francis Godwin (Director)
  • Kevin Maguire
View Company Profile

ID · 1c0c37db-ed65-4ecf-96ab-97fd522d3b7c

Violation Codes6
21 U.S.C. 351(a)(2)(B)21 CFR 21021 CFR 21121 CFR 211.84(d)(1)21 CFR 211.22(a)21 CFR 211.34

Full citation text and observation details available on the Dashboard.

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore K. Boeun Pharmaceutical Co., Ltd.
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.